Introduction: The efficacy of 177Lu-Dotatate was shown in the NETTER-1 trial, an international, open-label, multicentre phase III clinical trial that evaluated the safety and efficacy of 177Lu-Dotatate in patients with well-differentiated, advanced midgut neuroendocrine tumours (NETs) with evidence of disease progression. Recently, retreatment with peptide receptor radionuclide therapy (PRRT) has been proposed as a valid therapeutic option in patients without other effective options who had responded to initial PRRT; however, data on this therapeutic option are still inadequate. Case Report: In this report, we present the case of a patient who achieved a delayed complete radiological response after initial 177Lu-Dotatate treatment and who had a complete tumour response with PRRT retreatment 5 years later. Conclusions: This case report shows that, although rare, a complete, prolonged tumour response may occur in patients with advanced small-bowel NETs receiving PRRT. Retreatment with PRRT may be a valid option in cases of subsequent disease recurrence.

Efficacy of lutetium-peptide receptor radionuclide therapy in inducing prolonged tumour regression in small-bowel veuroendocrine tumours. A case of favourable response to retreatment after Initial objective response / Rinzivillo, M.; Prosperi, D.; Bartolomei, M.; Panareo, S.; Iannicelli, E.; Magi, L.; Panzuto, F.. - In: ONCOLOGY RESEARCH AND TREATMENT. - ISSN 2296-5262. - 44:5(2021), pp. 276-280. [10.1159/000515859]

Efficacy of lutetium-peptide receptor radionuclide therapy in inducing prolonged tumour regression in small-bowel veuroendocrine tumours. A case of favourable response to retreatment after Initial objective response

Rinzivillo M.;Prosperi D.;Iannicelli E.;Magi L.;Panzuto F.
2021

Abstract

Introduction: The efficacy of 177Lu-Dotatate was shown in the NETTER-1 trial, an international, open-label, multicentre phase III clinical trial that evaluated the safety and efficacy of 177Lu-Dotatate in patients with well-differentiated, advanced midgut neuroendocrine tumours (NETs) with evidence of disease progression. Recently, retreatment with peptide receptor radionuclide therapy (PRRT) has been proposed as a valid therapeutic option in patients without other effective options who had responded to initial PRRT; however, data on this therapeutic option are still inadequate. Case Report: In this report, we present the case of a patient who achieved a delayed complete radiological response after initial 177Lu-Dotatate treatment and who had a complete tumour response with PRRT retreatment 5 years later. Conclusions: This case report shows that, although rare, a complete, prolonged tumour response may occur in patients with advanced small-bowel NETs receiving PRRT. Retreatment with PRRT may be a valid option in cases of subsequent disease recurrence.
carcinoid tumour; everolimus; lutathera; peptide receptor radionuclide therapy; tumour regression; humans; lutetium; neoplasm recurrence; local; radioisotopes; receptors, peptide; retreatment; neuroendocrine tumors
01 Pubblicazione su rivista::01a Articolo in rivista
Efficacy of lutetium-peptide receptor radionuclide therapy in inducing prolonged tumour regression in small-bowel veuroendocrine tumours. A case of favourable response to retreatment after Initial objective response / Rinzivillo, M.; Prosperi, D.; Bartolomei, M.; Panareo, S.; Iannicelli, E.; Magi, L.; Panzuto, F.. - In: ONCOLOGY RESEARCH AND TREATMENT. - ISSN 2296-5262. - 44:5(2021), pp. 276-280. [10.1159/000515859]
File allegati a questo prodotto
File Dimensione Formato  
Rinzivillo_Efficacy_2021.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 204.75 kB
Formato Adobe PDF
204.75 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1611849
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact